management of parkinson’s disease
DESCRIPTION
It contains the Management of Parkinson's disease and i think it will be most useful to medical students to refer.TRANSCRIPT
![Page 1: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/1.jpg)
MANAGEMENT OF PARKINSON’S DISEASE
AAM. AMJATHMEDICINE 4TH BATCH FHCS-EUSL
![Page 2: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/2.jpg)
Objectives
• To Understand the Goals in Management of Parkinson’s Disease.
• Describe the Pharmacological Intervention in Parkinson’s Disease.
• Describe the Non-Pharmacological Intervention in Parkinson’s Disease.
• Describe the Surgical Treatments in Parkinson’s Disease.
![Page 3: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/3.jpg)
![Page 4: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/4.jpg)
![Page 5: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/5.jpg)
Goals of Management• Maintain the function• Avoid drug-induced complications
• In the Tx of PD,
BradykinesiaTremorRigidityAbnormal posture
Respond Early in illness
![Page 6: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/6.jpg)
• But…
Cognitive symptomsHypophoniaAutonomic dysfunctionBalance difficulties
Respond Poorly
![Page 7: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/7.jpg)
Pharmacological Management of Parkinson’s Disease.
Drugs used in PD1. Levodopa and Carbidopa2. Anticholinergics(Trihexyphenidyl, Benztropine)3. Amantadine4. Catechol-O-methyltransferase inhibitors (COMT
inhibitors5. Monoamine oxidase type B (MAO-B)(Give temporary relief from the symptoms of the disorder, but not arrest or reverse the neuronal degeneration. )
![Page 8: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/8.jpg)
Pharmacological Therapy in early PD
• ‘Early disease’ refers to PD in people who have developed functional disability and require symptomatic therapy.
• There is no single drug of choice in the initial pharmacotherapy of early PD.
![Page 9: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/9.jpg)
Options for initial pharmacotherapy in early PD
![Page 10: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/10.jpg)
• The dose of levodopa should be kept as low as possible to maintain good function in order to reduce the development of motor complications.
• Beta blockers used in the symptomatic treatment of selected people with postural tremor in PD.
• Anticholinergics may be used as a symptomatic treatment typically in young people with early PD and severe tremor
![Page 11: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/11.jpg)
Pharmacological therapy in later PD
• ‘Later disease’ refers to PD in people on levodopa who have developed motor complications.
• There is no single drug of choice in the pharmacotherapy of later PD.
• So, Adjuvant drugs are taken alongside with Levodopa for it.
• Ex: COMT inhibitors, MAO-B inhibitors, Dopamine agonist, Amantadine… etc.
![Page 12: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/12.jpg)
Options for adjuvant pharmacotherapy in later PD
![Page 13: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/13.jpg)
• Modified-release levodopa preparations may be used to reduce motor complications in people with later PD, but should not be drugs of first choice.
• MAO-B & COMT inhibitors may be used to reduce motor fluctuations and Amantadine may be used to reduce dyskinesia in people with later PD.
![Page 14: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/14.jpg)
![Page 15: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/15.jpg)
Non-Pharmacological Management of Parkinson’s Disease.
• It includes,
Rehabilitation.
Diet.
Physiotherapy
Speech & Language therapy
Occupational therapy
![Page 16: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/16.jpg)
Rehabilitation
• PhysiotherapyIt helps to improve the,
a. Mobility.b. Flexibility.c. Strength.d. Gait speed.e. Aerobic capacity.f. Quality of life.
![Page 17: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/17.jpg)
• Speech and language therapy
Particular consideration should be given to :a. improvement of vocal loudness and pitch range.
b. Ensuring an effective means of communication is maintained throughout the course of the disease.
c. review and management to support safety and efficiency of swallowing and to minimise the risk of aspiration.
![Page 18: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/18.jpg)
• Occupational therapy
Particular consideration should be given to :a. maintenance of work and family roles, home care
and leisure activities.
b. improvement and maintenance of transfers and mobility.
c. improvement of personal self-care activities, such as eating, drinking, washing and dressing.
![Page 19: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/19.jpg)
Diet
• Diet should include high fibre foods and plenty of water.
• When levodopa is introduced excessive proteins are discouraged due to competition between them to cross the BBB and intestine.
• So, To minimize interaction with proteins, levodopa is recommended to be taken 30 minutes before meals.
![Page 20: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/20.jpg)
Surgical Treatment• In refractory cases, Surgical Tx is considered.• Deep-brain stimulation (DBS) is presently the
most used Sx method.• Here Subthalamic nucleus(STN) or Globus pallidus
interna (GPi) is stimulated. • I˚ : Patients who suffer disability resulting from
levodopa-induced motor complications.• CI : a) Cognitive Impairment.
b) Major Psy.illnesses c) Substantial medical comorbidities d) Advanced age
![Page 21: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/21.jpg)
![Page 22: Management of parkinson’s disease](https://reader033.vdocuments.mx/reader033/viewer/2022051111/555060cab4c905ae3f8b53a9/html5/thumbnails/22.jpg)